Dr. Reddy’s partners Takeda for Qdenga vaccine in India.

Dr. Reddy’s Laboratories Limited

has entered an exclusive collaboration with Takeda to promote and distribute Qdenga in India’s pediatric and adult private market. Qdenga is India’s first CDSCO-approved dengue vaccine. The agreement covers promotion and distribution of the dengue vaccine in the private market for both children and adults. This gives Dr. Reddy’s access to a new vaccine product in a high-need area. It expands the company’s specialty portfolio beyond its core generics and branded business. The key development is the exclusive deal for India’s first approved dengue vaccine. It adds a new growth avenue for Dr. Reddy’s in vaccines. Peers in the pharma and vaccine space may see limited direct impact. Risks include slower private market uptake, pricing pressure or delayed commercial availability. We have no financial interest in this news.